Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.61 |
| ▸ | CDK2 | P24941 | 8/20 | 0.61 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269907 | 0.94 | IGF1R (0.69) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL1269162 | 0.94 | IGF1R (0.69) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL1270095 | 0.93 | IGF1R (0.58) | IGF1RCDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL1269041 | 0.91 | IGF1R (0.70) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL1269776 | 0.91 | IGF1R (0.59) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL1269833 | 0.91 | IGF1R (0.60) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL1268768 | 0.91 | IGF1R (0.59) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL1269241 | 0.89 | IGF1R (0.59) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL3934592 | 0.87 | IGF1R (0.71) | IGF1RCDK2CCNE2CCNE1 | |
| SCHEMBL1269743 | 0.87 | IGF1R (0.71) | IGF1RCDK2CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041138-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8263765-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| US-7879855-B2 | administering (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide, for the treatment of cancers of the colon, lung, ovary, and pancreas; anticarcinogenic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-24 | — | — | US | disclosed |
| US-7534792-B2 | e.g. 1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-methylpyrrolidine-2-carboxamide; tyrosine kinase inhibitor; anticarcinogenic, antiproliferative agent, neurodegenerative diseases; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885CDK2 97/4885CCNE2 1617/4885 |
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885CDK2 97/4885CCNE2 1617/4885 |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885CDK2 97/4885CCNE2 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.